Primary Objectives To determine safety of MBG453 given in combination with spartalizumab and
SRS in patients with recurrent GBM.
To assess the preliminary anti-tumor activity using the following measures:
1. To estimate overall survival
2. To estimate progression-free survival
3. To estimate Radiographic Response (RANO and iRANO)
4. To evaluate pain for patients undergoing the treatment of anti-TIM3 and anti-PD1 in
combination with SRS
1. To assess the effects of MGB453, spartalizumab and their combination with SRS on immune
cells in peripheral blood, including but not limited to the T cell compartments, myeloid
cells, and serum proteins (cytokines and other immune modulators).
2. To assess the pharmacodynamic activity in tumor tissue and peripheral blood in treated
subjects who undergo tumor biopsies as clinically indicated.
3. To explore potential associations between biomarker measures and anti-tumor activity by
analyzing markers of inflammation, immune activation, host tumor growth factors, and
tumor-derived proteins in the pre-treatment and on-treatment setting.
4. To explore characteristics of tumor immune microenvironment change after the treatment.
Patients receive MBG453 and spartalizumab intravenously (IV) over 30 minutes each on Day 1.
Patients then undergo stereotactic radiosurgery on Day 8 per standard of care. Courses with
MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or
After completion of study treatment, patients are followed up every 3 months thereafter.
1. Patients must provide written informed consent prior to any screening procedures.
2. Age 18 years or older.
3. Willing and able to comply with scheduled visits, treatment plan and laboratory tests
4. Must have WHO Grade IV Glioblastoma or gliosarcoma based on histopathological OR
5. Patients tumor target (GTV) should be ≤ 5 cm.
6. a) Must have received first-line multimodal therapy with surgery (resection or biopsy)
followed by radiation and Temozolomide (unless known MGMT promoter unmethylated) AND
b) Must have completed at least 21 days of combination and Temozolomide therapy
(unless known MGMT promoter unmethylated. . An interval of at least 12 weeks after the
end of combination radiation therapy + Temozolomide is required unless there is: i.)
Histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside
of the radiotherapy treatment field. (*NOTE: Patients treated with Optune device or
who received Gliadel wafers placed during the first surgery are eligible.
7. Must have no more than 2 recurrences of either GBM or gliosarcoma. Recurrence must be
confirmed by diagnostic biopsy/surgery with local pathology review OR
contrast-enhanced MRI measurable by RANO criteria. (*NOTE: Patients diagnosed with WHO
Grade III that undergo surgical resection and are found to have WHO Grade IV or
gliosarcoma are considered eligible).
8. Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is
allowed but the subject must have either histopathologic confirmation of recurrent
tumor, or new enhancement on MRI outside of the radiotherapy treatment field
9. Karnofsky Performance Status ≥ 70
10. Must have ability to undergo MRI scans
11. Must be > 30 days since last chemotherapy
12. Must have recovered from severe toxicity of prior therapy. (NOTE: Patients who undergo
surgical resection must have recovered from surgery (at least 2 weeks) before starting
13. Subjects must have normal organ and marrow function as defined below:
WBC ≥ 2,000/mcL absolute neutrophil count ≥ 1,500/mcL platelets ≥ 100,000/mcL
hemoglobin ≥ 9.0 g/dL lymphocytes ≥ 500/mcL total bilirubin ≤ 1.5X institutional upper
limit of normal AST/ALT ≤ 3.0 X institutional upper limit of normal creatinine ≤ 1.5X
institutional upper limit of normal OR Creatinine clearance (CrCl) ≥ 50 mL/min (using
the Cockcroft-Gault formula)
14. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
test within -7 days prior to the start of therapy. Women must not be breastfeeding.
15. Women of child bearing potential (WOCBP) and men must use a reliable form of
contraception during the study treatment period and for 150 days following the last
dose of study drug. In order for a woman to be determined not of child-bearing
potential, she must have ≥ 12 months of non-therapy-induced amenorrhea or be
1. History of other malignancy, unless the patient has been disease-free for at ≥5 years.
Curatively treated basal or squamous cell carcinoma of the skin, totally excised
melanoma of stage IIA or lower, low or intermediate-grade localized prostate cancer
(Gleason sum ≤7), and curatively-treated carcinoma in situ of the cervix, breast, or
bladder are allowed regardless.
2. Any known metastatic extracranial or leptomeningeal disease.
3. Evidence of acute intracranial / intra-tumoral hemorrhage
4. History of organ or hematopoietic stem cell (HSC) transplant
5. Receiving greater than 4 mg dexamethasone/day (or equivalent amount of an alternative
corticosteroid) for a minimum of 5 days prior to screening visit. Subjects with an
autoimmune condition requiring systemic treatment with either corticosteroids (> 10 mg
daily prednisone or equivalent) or other immunosuppressive medications within 14 days
of study entry *NOTE: Inhaled or topical steroids, and adrenal replacement steroid
doses > 10 mg daily prednisone or equivalent, are permitted in the absence of active
6. Prior treatment with immune-modulating therapy, other than steroids.
7. Pregnant or nursing (lactating) women
8. Known positive history of HIV, active Hepatitis B, and/or active Hepatitis C
9. Subjects with active, or recent history of known or suspected autoimmune disease.
Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone
replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring
systemic treatment, or conditions not expected to recur in the absence of an external
trigger are permitted to enroll
10. Major surgery, outside of a craniotomy/resection, within 2 weeks of the first dose of
study treatment (mediastinoscopy, insertion of a central venous access device, and
insertion of a feeding tube are not considered major surgery).
11. Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within
4 weeks of initiation of study treatment
12. Any serious or uncontrolled medical disorder that, in the opinion of the investigator,
may increase the risk associated with study participation or study drug
administration, impair the ability of the subject to receive protocol therapy, or
interfere with the interpretation of study results.
13. Subjects with interstitial lung disease that is symptomatic or may interfere with the
detection or management of suspected drug-related pulmonary toxicity
14. History of evidence upon physical/neurological examination of other central nervous
system condition (i.e. seizures, abscess) unrelated to cancer, unless adequately
controlled by medication or considered not potentially interfering with protocol
15. History of allergy or hypersensitivity to study drug components.
16. Prisoners or subjects who are involuntarily incarcerated.
17. Subjects who are compulsorily detained for treatment of either a psychiatric or
physical (e.g. infections disease) illness.